2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048
1 signal in the last 90 days.
The order this company entered each market — oldest to newest
Harbour BioMed reports strong 2025 financial results
Fangzhou Inc. Reports Profitable First Half 2025
Sign up to see the full signal feed
How Otsuka Holdings Co., Ltd.'s international expansion compares to its competitors
Otsuka Holdings Co., Ltd.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Otsuka Holdings Co., Ltd.You | 1 | 1 | -100% | 1 | 12 |
【東京：リモート】グループ共通IT基盤の社内SE（クラウドインフラ管理者）
View postingTokyo, Tokyo, Japan · 3mo ago
ITエンジニア
View postingTokyo, Japan · last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Otsuka's Abilify Asimtufai, a long-acting injectable aripiprazole for schizophrenia and bipolar disorder, approved in Korea. It allows bimonthly dosing, improving on previous monthly injections.
Fangzhou Inc. has launched Otsuka's third-generation leukemia drug Ponatinib on its platform, expanding access to this advanced treatment.
Curient is gaining attention with its next-generation ADC platform technology, aiming to compete globally in the rapidly growing ADC market for cancer treatment.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Otsuka Holdings Co., Ltd.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
